Frontlight ResearchEarly access
CompletedPhase 3
Safety & Efffficacy of Genakumab in Patients With Frequent Flares
Key facts
- Who runs it
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 313 people enrolled
- Started
- 11 Jan 2023
- Ended
- 3 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- genakumab
- placebo for Diprospan
- placebo for genakumab
- Diprospan
- Record updated
- 18 December 2024
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Male or female, 18 years ≤ age ≤75 years
- BMI≤40kg/m2
- Meeting ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout
- Start of acute gout flare within 4 days prior to enrolled
- History of ≥ 2 gout flares within the 12 months prior to study start
- Evidence of contraindication (absolute or relative), or intolerance, or lack of efficacy for either NSAIDs and/or colchicines
- Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)
Who cannot take part
- -
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).
The 2 groups in the trial
- GenakumabTreatment being tested
Genakumab 200mg s.c
Treatment: genakumab and placebo for Diprospan
- DiprospanExisting treatment, for comparison
Diprospan 7mg im
Treatment: placebo for genakumab and Diprospan
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety & Efficacy of Genakumab in Patients With Frequent Flares
- Publications
- Record updated
- 18 December 2024